By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
High velocity Internet services for Metropolitan Regions - 2Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- 3Spain breaks jobs record with 22 million Social Security contributors
- 4Poland open to German troops to help secure Ukraine ceasefire
- 5New York to require social media platforms to display mental health warnings
- Style Narratives: A Survey of \Patterns and Styles Assessed\ Design
- Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
- 5 things for parents to know about changes to kids vaccine schedule
- Finding China: Four Urban areas for a Remarkable Excursion
- 6 Eyewear Brands Worth Purchasing
- 5 Side interests That Work on Psychological wellness
- He suddenly couldn't speak in space. NASA astronaut says his medical scare remains a mystery
- Astrophotographer captures spectacular photo of Antennae Galaxies dueling in deep space
- South African army arrive in crime hotspots to help tackle gangs
